Literature DB >> 23327685

Ovulatory effects of flutamide in the polycystic ovary syndrome.

Roberto Paradisi1, Raffaella Fabbri, Cesare Battaglia, Stefano Venturoli.   

Abstract

The long-term effects and tolerability of flutamide (Flu) on the menstrual cycle and the ovulatory function of hyperandrogenic women with or without polycystic ovary syndrome (PCOS) were investigated. The study included 118 white women with the diagnosis of various forms of hyperandrogenism (80 PCOS and 38 non-PCOS patients). Patients received Flu for three years at dosages that declined each of the three years (250, 125 and 62.5 mg/day). Sex steroid, ovulatory function and menstrual profile at baseline and during each year of Flu treatment were evaluated. Flu therapy showed a significant increase in the percentage of cycles that were ovulatory (with progesterone concentrations greater than 4 ng/ml in mid-luteal phase) and concomitant regularization of the menstrual profile in PCOS patients. A luteinizing hormone decrease and an estrone, estradiol and 17-hydroxyprogesterone increase are also observed during treatment. Regular cycles persisted in non-PCOS patients. The results were maintained during the three years of treatment. The study suggests that Flu is a satisfactory therapeutic regimen of the chronic anovulation and the irregularities of the menstrual cycle in hyperandrogenic PCOS patients in the long run.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23327685     DOI: 10.3109/09513590.2012.754876

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  14 in total

1.  PCOS: Animal models for PCOS - not the real thing.

Authors:  Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2017-05-05       Impact factor: 43.330

Review 2.  Ovulation: Parallels With Inflammatory Processes.

Authors:  Diane M Duffy; CheMyong Ko; Misung Jo; Mats Brannstrom; Thomas E Curry
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.

Authors:  M Kupreeva; A Diane; R Lehner; R Watts; M Ghosh; S Proctor; D Vine
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

4.  Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.

Authors:  Aimee S L Caldwell; Melissa C Edwards; Reena Desai; Mark Jimenez; Robert B Gilchrist; David J Handelsman; Kirsty A Walters
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

Review 5.  Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.

Authors:  Viktor V Smirnov; Narasimha M Beeraka; Dmitry Yu Butko; Vladimir N Nikolenko; Sergey A Bondarev; Evgeniy E Achkasov; Mikhail Y Sinelnikov; P R Hemanth Vikram
Journal:  Reprod Sci       Date:  2022-06-28       Impact factor: 2.924

6.  Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.

Authors:  Genevieve E Ryan; Shaddy Malik; Pamela L Mellon
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

7.  Androgen Receptors in Multiple Organ Systems Provide Molecular Gateways to Polycystic Ovary Syndrome.

Authors:  David H Abbott; Jon E Levine; Daniel A Dumesic
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

Review 8.  The role of gonadotropin-releasing hormone neurons in polycystic ovary syndrome.

Authors:  Christopher R McCartney; Rebecca E Campbell; John C Marshall; Suzanne M Moenter
Journal:  J Neuroendocrinol       Date:  2022-01-26       Impact factor: 3.870

9.  Effect of Metformin and Flutamide on Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under Hypocaloric Diet.

Authors:  Mania Amiri; Masoumeh Golsorkhtabaramiri; Sedigheh Esmaeilzadeh; Faeze Ghofrani; Ali Bijani; Leila Ghorbani; Moloud Agajani Delavar
Journal:  J Reprod Infertil       Date:  2014-10

10.  Constitutive expression of Steroidogenic factor-1 (NR5A1) disrupts ovarian functions, fertility, and metabolic homeostasis in female mice.

Authors:  Emmi Rotgers; Barbara Nicol; Karina Rodriguez; Saniya Rattan; Jodi A Flaws; Humphrey Hung-Chang Yao
Journal:  FASEB J       Date:  2021-08       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.